Page 398«..1020..397398399400..410420..»

Global Cell and Gene Therapy Market Investor/Opportunities Report 2022: Evaluate the Current/Future Potential Over the Coming Decades – GlobeNewswire

Posted: June 13, 2022 at 2:13 am

Dublin, June 08, 2022 (GLOBE NEWSWIRE) -- The "Investor Series: Opportunities in the Cell and Gene Therapy Market" report has been added to ResearchAndMarkets.com's offering.

The report provides detailed information on the cell and gene therapy industry, covering both core and peripheral products, and affiliated services.

One of the key objectives of the report was to evaluate the current opportunity and the future potential of cell and gene therapies over the coming decades. We have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2021-2035.

It offers a technical and financial perspective on how the opportunity in this domain is likely to evolve, in terms of future business success, over the coming decade. The information in this report has been presented across multiple deliverables, featuring MS Excel sheets (some of which include interactive elements) and an MS PowerPoint deck, which summarizes the key takeaways from the project, and insights drawn from the curated data.

Contemporary medical science has traced thousands of clinical conditions to a genetic cause. Cancer, a life-threatening disease, also has genetic origins, and is considered among the leading causes of death across the globe. In fact, the World Health Organization (WHO) has reported that close to 10 million cancer related deaths annually, across the world.

Moreover, experts believe that there are over 7,000 different types of rare diseases (including some rare forms of cancer), most of which originate as a consequence of genetic anomalies. The majority of the aforementioned conditions are still considered incurable. As a result, these disease areas are characterized by a significant unmet need for curative interventions; and therefore, considered among the most lucrative opportunity areas for biopharmaceutical developers.

For example, ZOLGENSMA, a blockbuster product developed by Novartis, and indicated for the treatment of spinal muscular atrophy, generated net revenues of approximately USD 1.35 billion in 2021 alone. The first gene therapy trial was conducted in 1990, and it took almost three decades for the first of such interventions to enter the market.

Given recent developments in genetic manipulation, cell biology and molecular targeting, a number of highly specific interventions have been developed against prominent types of cancers and certain rare genetic conditions. Currently, there are over 20 cell and gene therapies approved for use in the United States alone.

During the COVID-19 pandemic, the pace of R&D in this field slowed down - a consequence of complex manufacturing protocols, extensive logistical considerations and supply chain-related concerns. However, the field still witnessed a considerable inflow of capital, with over USD 21 billion invested into various companies since the start of the pandemic.

With over 1,200 product candidates in various stages of development, experts suggest that, by 2025, the US FDA may start approving around 10 to 20 cell and gene therapy products, on an annual basis. It is likely that, over the next two decades, gene therapies facilitate the evolution of medical practice from a treatment-based paradigm to a prevention-focused approach.

Despite the fact that niche startups are spearheading the innovation in this domain, several big pharma players are also actively acquiring capabilities related to upcoming advanced therapy medical products (ATMPs). Prominent players in the field, such as Juno Therapeutics, AveXis, and Kite Pharma, have been acquired as a consequence of the rapid expertise building efforts of more established pharma companies.

Moreover, gene therapy-focused businesses that have gone public, have experienced considerable growth in share value as their respective products / product candidate progressed through the various stages of development. Taking into consideration both the historical and contemporary scenario, the cell and gene therapies market continues to present lucrative investment opportunities for both short- and long-term investors.

The report features the following details:

For more information about this report visit https://www.researchandmarkets.com/r/xsaxrs

Link:
Global Cell and Gene Therapy Market Investor/Opportunities Report 2022: Evaluate the Current/Future Potential Over the Coming Decades - GlobeNewswire

Posted in Gene therapy | Comments Off on Global Cell and Gene Therapy Market Investor/Opportunities Report 2022: Evaluate the Current/Future Potential Over the Coming Decades – GlobeNewswire

Coave Therapeutics and ABL enter into strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for…

Posted: June 13, 2022 at 2:13 am

Two-stage collaboration aims to accelerate development of high-capacity manufacturing processes for AAV-based products and secure Coave's infrastructure needs to set up its process development capabilities

PARIS and STRASBOURG, France, June 9, 2022 /PRNewswire/ -- Coave Therapeutics ('Coave'), a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases, and ABL, a pure play contract development and manufacturing organization (CDMO) specialized in the development and manufacturing of viruses for vaccine candidates, gene and cancer therapies, today announce that they have entered into a strategic collaboration to develop gene therapy manufacturing processes. The financial terms are not disclosed.

Under the two-stage collaboration both companies will initially combine their complementary expertise to co-develop manufacturing technologies for AAV-based gene therapy products. ABL and Coave's process development teams will work jointly in ABL's state-of-the-art GMP facility in Lyon, France.

The second stage of the collaboration provides Coave with an exclusive option to secure process development capacity and laboratory space within ABL's facility. This will enable Coave to further develop and scale-up manufacturing technologies for AAV-based products, including its proprietary next-generationAAV-Ligand Conjugate vectors (ALIGATER) platform. The deal will also strengthen Coave's ability to generate large-scale and high-quality gene therapy products based on this new generation of advanced AAV vectors.

"Our collaboration with ABL, a best-in-class and complementary partner for Coave, is a major step in our strategy towards the vertical integration of our R&D capacities, which will be crucial in enabling us to control the development and manufacture of our pipeline products in an end-to-end manner. The manufacturing processes developed through this partnership will be critical in the path to achieving our future clinical and commercial development milestones, in particular for our CNS programs addressing large patient populations," said Rodolphe Clerval, CEO, Coave Therapeutics.

Patrick Mahieux, General Manager ABL Europe, said: "We are delighted to join forces with Coave, a fellow French company. This exclusive partnership aims to bring together our knowledge and expertise to co-develop a state-of-the-art manufacturing process for viral vectors used in cell and gene therapies. We are excited to welcome Coave's team of expert scientists to our facilities in Lyon to jointly accelerate the development of an AAV manufacturing platform. We look forward to a long-term partnership enabling the development and manufacturing of innovative cell and gene therapy treatments in France."

About Coave Therapeutics

Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases.

Coave Therapeutics' next-generation AAV-Ligand Conjugate ('ALIGATER') platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases.

The company is advancing a pipeline of novel therapies targeting CNS and eye diseases where targeted gene therapy using chemically-modified AAVs has the potential to be most effective.

Coave Therapeutics, which is headquartered in Paris (France), is backed by leading international life science and strategic investors Seroba Life Sciences, Tha Open Innovation, eureKARE, Fund+, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital and Sham Innovation Sant/Turenne.

For more information, please visit http://www.coavetx.comor follow us on LinkedIn

About ABL, an Institut Mrieux company

ABL is a pure play contract development and manufacturing organization (CDMO) specialized in the development and manufacturing of virus for vaccine candidates, gene and cancer therapies. ABL's mission is to provide GMP viral vectors from early-stage to market, contributing to the success of its clients' immunotherapy innovations. ABL's CDMO services include bulk drug substance, fill/finish of drug product, process and assay development, and bioanalytical testing.

ABL is a subsidiary of the Institut Mrieux and operates from various locations in Europe and in the US.

http://www.abl-biomanufacturing.com

CONTACTS

Coave TherapeuticsRodolphe Clerval, CEO[emailprotected]

MEDiSTRAVA ConsultingSylvie Berrebi, Eleanor Perkin, Mark Swallow PhD[emailprotected] Tel: +44 203 928 6900

ABLJustine Chabrol, Head of Communications & CSR[emailprotected]

Andrew Lloyd & AssociatesEmilie Chouinard Saffiyah Khalique [emailprotected] [emailprotected] Tel: +44 1273 952 481@ALA_Group

SOURCE Coave Therapeutics and ABL

Read the original:
Coave Therapeutics and ABL enter into strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for...

Posted in Gene therapy | Comments Off on Coave Therapeutics and ABL enter into strategic collaboration to develop gene therapy manufacturing processes and create joint capabilities for…

Adeno-Associated Virus Vectors in Gene Therapy Research Report 2022: Market Insight, Epidemiology and Market Forecasts 2019-2032 -…

Posted: June 13, 2022 at 2:13 am

DUBLIN--(BUSINESS WIRE)--The "Adeno-Associated Virus Vectors in Gene Therapy - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

The Adeno-Associated Virus Vectors in Gene Therapy market report provides current treatment practices, emerging drugs, Adeno-Associated Virus Vectors in Gene Therapy market share of the individual therapies, current and forecasted Adeno-Associated Virus Vectors in Gene Therapy market Size from 2019 to 2032 segmented by seven major markets.

The Report also covers current Adeno-Associated Virus Vectors in Gene Therapy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Adeno-Associated Virus Vectors in Gene Therapy Disease Understanding and Treatment Algorithm

The Adeno-Associated Virus Vectors in Gene Therapy market report gives a thorough understanding of the Adeno-Associated Virus Vectors in Gene Therapy by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Adeno-Associated Virus Vectors in Gene Therapy.

Treatment

It covers the details of conventional and current medical therapies available in the Adeno-Associated Virus Vectors in Gene Therapy market for the treatment of the condition. It also provides Adeno-Associated Virus Vectors in Gene Therapy treatment algorithms and guidelines in the United States, Europe, and Japan.

Adeno-Associated Virus Vectors in Gene Therapy Epidemiology

The Adeno-Associated Virus Vectors in Gene Therapy epidemiology division provide insights about historical and current Adeno-Associated Virus Vectors in Gene Therapy patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted Adeno-Associated Virus Vectors in Gene Therapy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

Adeno-Associated Virus Vectors in Gene Therapy Drug Chapters

Drug chapter segment of the Adeno-Associated Virus Vectors in Gene Therapy report encloses the detailed analysis of Adeno-Associated Virus Vectors in Gene Therapy marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Adeno-Associated Virus Vectors in Gene Therapy clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Adeno-Associated Virus Vectors in Gene Therapy treatment.

Adeno-Associated Virus Vectors in Gene Therapy Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Adeno-Associated Virus Vectors in Gene Therapy treatment.

Adeno-Associated Virus Vectors in Gene Therapy Market Outlook

The Adeno-Associated Virus Vectors in Gene Therapy market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Adeno-Associated Virus Vectors in Gene Therapy market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Adeno-Associated Virus Vectors in Gene Therapy market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to the publisher, Adeno-Associated Virus Vectors in Gene Therapy market in 7MM is expected to change in the study period 2019-2032.

Adeno-Associated Virus Vectors in Gene Therapy Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Adeno-Associated Virus Vectors in Gene Therapy market or expected to get launched in the market during the study period 2019-2032. The analysis covers Adeno-Associated Virus Vectors in Gene Therapy market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Adeno-Associated Virus Vectors in Gene Therapy Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Adeno-Associated Virus Vectors in Gene Therapy key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Adeno-Associated Virus Vectors in Gene Therapy emerging therapies.

Reimbursement Scenario in Adeno-Associated Virus Vectors in Gene Therapy

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL-Views

To keep up with current market trends, we take KOLs and SME's opinion working in Adeno-Associated Virus Vectors in Gene Therapy domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Adeno-Associated Virus Vectors in Gene Therapy market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

The publisher performs Competitive and Market Intelligence analysis of the Adeno-Associated Virus Vectors in Gene Therapy Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Key Topics Covered:

1. Key Insights

2. Executive Summary of Adeno-Associated Virus Vectors in Gene Therapy

3. Competitive Intelligence Analysis for Adeno-Associated Virus Vectors in Gene Therapy

4. Adeno-Associated Virus Vectors in Gene Therapy: Market Overview at a Glance

4.1. Adeno-Associated Virus Vectors in Gene Therapy Total Market Share (%) Distribution in 2019

4.2. Adeno-Associated Virus Vectors in Gene Therapy Total Market Share (%) Distribution in 2032

5. Adeno-Associated Virus Vectors in Gene Therapy: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Adeno-Associated Virus Vectors in Gene Therapy Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Adeno-Associated Virus Vectors in Gene Therapy Epidemiology Scenario in the 7MM (2019-2032)

7.4. United States Epidemiology

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.2. France Epidemiology

7.5.3. Italy Epidemiology

7.5.4. Spain Epidemiology

7.5.5. United Kingdom Epidemiology

7.5.6. Japan Epidemiology

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Adeno-Associated Virus Vectors in Gene Therapy Treatment and Management

8.2. Adeno-Associated Virus Vectors in Gene Therapy Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Adeno-Associated Virus Vectors in Gene Therapy Treatment

11. Marketed Products

12. Emerging Therapies

13. Adeno-Associated Virus Vectors in Gene Therapy: Seven Major Market Analysis

13.1. Key Findings

13.2. Adeno-Associated Virus Vectors in Gene Therapy Market Size in 7MM

13.3. Adeno-Associated Virus Vectors in Gene Therapy Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Adeno-Associated Virus Vectors in Gene Therapy Total Market Size in the United States

15.1.2. Adeno-Associated Virus Vectors in Gene Therapy Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.4. France Market Size

15.5. Italy Market Size

15.6. Spain Market Size

15.7. United Kingdom Market Size

15.8. Japan Market Outlook

15.8.1. Japan Market Size

16. Access and Reimbursement Overview of Adeno-Associated Virus Vectors in Gene Therapy

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/t0ddt0

Read more from the original source:
Adeno-Associated Virus Vectors in Gene Therapy Research Report 2022: Market Insight, Epidemiology and Market Forecasts 2019-2032 -...

Posted in Gene therapy | Comments Off on Adeno-Associated Virus Vectors in Gene Therapy Research Report 2022: Market Insight, Epidemiology and Market Forecasts 2019-2032 -…

Plant biologist nominated for prestigious early career award – University of Georgia

Posted: June 13, 2022 at 2:13 am

UGAs Schmitz named finalist for 2022 Blavatnik National Awards for Young Scientists

University of Georgia faculty member Robert Schmitz was recently chosen as a finalist for a national award for young scientists. The Blavatnik National Awards for Young Scientists is the worlds largest unrestricted prize honoring early career scientists and engineers.

Schmitz is a plant biologist who performs groundbreaking research on plant epigeneticsthe chemical modifications to DNA and associated proteins that alter gene expressionto unlock new methods to increase agricultural sustainability and food security. He found that some plant epigenetic mechanisms differ from those of animals, and that this unique mode of epigenetic modification impacts plant evolution and can inform crop breeding.

His discoveries in the epigenetics of maize offer plant breeders targets in the maize genome to improve crop performance, such as overall yield or resistance to disease. Schmitzs work, as described in the Blavatnik Awards finalists announcement, has set in motion the discovery and creation of new plant biotechnology that could help feed the world.

The honorees were chosen from a highly competitive pool of 309 nominees from 150 leading universities and scientific institutions from 38 states across the United States.

From the announced group of finalists, three winnersin life sciences, chemistry, and physical sciences and engineeringwill be named on June 29, each receiving $250,000 as a Blavatnik National Awards Laureate.

I am thankful for this recognition and grateful to past and present lab members that have advanced our understanding of plant epigenetics, said Schmitz, who holds a UGA Foundation Professorship of Plant Sciences and is the Lars G. Ljungdahl Distinguished Investigator. We are fortunate to work alongside so many great colleagues in the department of genetics at the University of Georgia.

Three independent jurieseach representing one of the award categoriesselected the finalists and will determine the winning laureates. Laureates must be faculty-level scientific researchers, 42 years of age or younger, and are nominated to the competition by their university or research institution.

At his initial hire as an assistant professor, Bob was clearly a rising star in the field of epigenetics, said Nancy Manley, Distinguished Research Professor and head of the Franklin College of Arts and Sciences department of genetics. This award reflects what we know alreadythat his creativity, productivity and leadership while a faculty member at UGA have more than borne out that early promise, and promise even more great things in the future.

This is an extraordinary honor and I would like to acknowledge the Blavatnik National Awards for Young Scientists for recognizing the importance of agricultural research as part of their life sciences portfolio, Schmitz said.

Read more:
Plant biologist nominated for prestigious early career award - University of Georgia

Posted in Epigenetics | Comments Off on Plant biologist nominated for prestigious early career award – University of Georgia

Omega Therapeutics (OMGA) Research Analysts’ Weekly Ratings Changes – Defense World

Posted: June 13, 2022 at 2:13 am

A number of firms have modified their ratings and price targets on shares of Omega Therapeutics (NASDAQ: OMGA) recently:

Omega Therapeutics stock opened at $3.70 on Friday. The company has a debt-to-equity ratio of 0.11, a quick ratio of 15.23 and a current ratio of 15.23. The firm has a market capitalization of $177.05 million and a price-to-earnings ratio of -0.77. Omega Therapeutics, Inc. has a fifty-two week low of $1.98 and a fifty-two week high of $31.41. The stocks fifty day moving average is $3.85 and its two-hundred day moving average is $8.97.

Omega Therapeutics (NASDAQ:OMGA Get Rating) last posted its quarterly earnings data on Thursday, March 10th. The company reported ($0.44) EPS for the quarter, beating analysts consensus estimates of ($0.57) by $0.13. The company had revenue of $0.14 million for the quarter. As a group, sell-side analysts forecast that Omega Therapeutics, Inc. will post -2.17 EPS for the current fiscal year.

Omega Therapeutics, Inc operates as a development-stage biopharmaceutical company. Its OMEGA Epigenomic Programming platform is designed to coopt nature's operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. The company is developing omega epigenomic controller (OEC) candidates to up-regulate the expression of HNF4a, a transcriptional master regulator as a potential way to restore liver-cell function in patients suffering from chronic liver diseases; to control the expression of genes that have been strongly linked to cell-growth inhibition in patients with diabetes and other conditions to restore the capacity for corneal regeneration; to down-regulate expression of the CXCL1, 2, 3, and IL-8 gene cluster; to control expression of genes implicated in patients with idiopathic pulmonary fibrosis to halt or reverse disease progression and improve disease outcomes; to down-regulate the expression of SFRP1, a protein that inhibits hair growth; and to treat non-small cell lung cancer and small cell lung cancer.

Read More

Receive News & Ratings for Omega Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omega Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Visit link:
Omega Therapeutics (OMGA) Research Analysts' Weekly Ratings Changes - Defense World

Posted in Epigenetics | Comments Off on Omega Therapeutics (OMGA) Research Analysts’ Weekly Ratings Changes – Defense World

Introducing Cantata Bio, Inventive Multimodal Solutions for Accelerating Genome-based R&D – Business Wire

Posted: June 13, 2022 at 2:13 am

CAMBRIDGE, Mass. & SCOTTS VALLEY, Calif.--(BUSINESS WIRE)--Cantata Bio launched today, with the mission of enabling researchers to address the worlds most challenging scientific questions, from human disease to agricultural sustainability, using leading-edge multi-dimensional NGS technologies. The company is a result of the merger between Dovetail Genomics, the industry leader in advanced proximity ligation genomic solutions, and Arc Bio, which develops novel, proprietary metagenomic tools for accurate and sensitive microbial profiling. Committed to delivering the most innovative NGS-based solutions, Cantata Bio comprises three business units, Epigenetics & Genome Structure, Microbial Profiling, and Genetic Analysis Solutions.

The benefits of this merger to both our customers and the companies were clear - accelerated innovation, the potential to aggregate multimodal data to better service our partners, and streamlined operations, said Todd Dickinson, CEO of Cantata Bio. Cantata Bio aims to dramatically accelerate advances in the life sciences industry with key competencies, including integrated metagenomics workflows for understanding the interplay between microbes and disease, and unique NGS sequencing assays that deliver industry-leading long-range data empowering genome assembly, haplotype phasing, chromatin structure and epigenomic applications.

Serving on the Board of Directors for former Dovetail and Arc Bios parent company, EdenRoc Sciences, Todd Dickinson continues in the role of CEO for Cantata Bio. A life sciences executive with more than 20 years of genomics experience, Todd was a founding scientist of Illumina, holding a variety of technical and commercial executive roles both at Illumina and subsequently at Bionano Genomics.

Along with the company launch, Cantata Bio announced today its Dovetail TopoLink Kit, a revolutionary new assay delivering genomic interactions at unparalleled speed. With genomic interactions critical to understanding functional biology, the TopoLink Assay removes the bias introduced from motif-based assays, captures chromatin topology features with a higher rate of discovery, and offers superior accuracy in detecting chromatin loops, all in an unprecedented six hour sample-to-sequencing library workflow - less than half the time of traditional Hi-C approaches.

Cantata Bio has seen early demand for TopoLink, having already allocated the first several kits to members of its First Adopters Circle. These include Chris Mason, Professor of Genomics, Physiology, & Biophysics, and Director of Emerging Genome Technologies at Tempus Labs, David Sinclair, Professor in the Department of Genetics and co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School, Melissa Fullwood, Nanyang Assistant Professor at SBS, NTU and Junior Principal Investigator at CSI Singapore, and Emily Bernstein, Professor, and Dan Hasson, Associate Professor, at the Tisch Cancer Institute of the Icahn School of Medicine at Mount Sinai.

Cantata Bio and its newest product, the Dovetail TopoLink Kit, were announced today at Advances in Genome Biology and Technology (AGBT), where Cantata Bio is an official sponsor. To learn more about the Dovetail TopoLink Kit or Cantata Bio, visit suite 1825 throughout the conference, and join us for our launch party on the evening of June 7th during and after the Passport prizes/CLICK2WIN event. For more information, visit http://www.cantatabio.com.

About Cantata Bio

Cantata Bio is enabling researchers to solve tomorrows most challenging scientific problems through novel, multi-dimensional approaches that unlock access to genomic, epigenomic and metagenomic information at unprecedented levels. Combining proprietary technologies with platform solutions, services, and cutting-edge bioinformatics and software, our unique approaches are solving complex problems, including chromatin topology analysis, small and large structural variant detection, de novo chromosome assembly, haplotype phasing, metagenomics, and microbiome analysis. Our customers are positively impacting the fields of epigenetics, developmental biology, cancer research, evolutionary biology, infectious disease, and more. Cantata Bio is based in Scotts Valley, California and Cambridge, Massachusetts. For more information on Cantata Bio, its technology, and offerings, visit http://www.cantatabio.com.

Read more from the original source:
Introducing Cantata Bio, Inventive Multimodal Solutions for Accelerating Genome-based R&D - Business Wire

Posted in Epigenetics | Comments Off on Introducing Cantata Bio, Inventive Multimodal Solutions for Accelerating Genome-based R&D – Business Wire

Julee Cruise’s Career: How and where to watch Twin Peaks and all her TV appearances – Bolavip US

Posted: June 13, 2022 at 2:13 am

Julee Cruiseborn on December 1, 1956 in Iowa.Since childhood she has had a special affinity for the world of music. She studied French horn at Drake University and performed as a singer and actress in Minneapolis with the Children's Theatre Company. Her favorite role to play was Jinjur from Lyman Frank Baum's Oz books.

As a singer, songwriter and actress, she has recorded four studio albums: Floating into the Night, The Voice of Love, The Art of Being a Girl and My Secret Life. During the 80's she collaborated with figures such as Angelo Badalamenti (composer of Blue Velvet) and David Lynch (film director). Both have been the producers of his first two albums.

But fame and worldwide recognition came with her participation in the famous mystery series Twin Peaks. With an angelic voice, the singerperformed the song "Falling" in 1990, which became the orchestral theme for the television series. Thanks to its impact, she won Best Pop Instrumental awardat the 33rd Grammy Awards.

With her enveloping and ethereal voice, she was also a collaborator of many soundtracks, programs and television series of high popularity. Some like Scream, Psych in the episode "Dual Spires", Saturday Night Live in the 90's and one of her most remarkable projects, Blue Velvet.

Cruise married Editor-in-Chief and Vice President of Guideposts Publications, Eduard Grinnan. The two lived together, with their golden retriever puppy Grace, in a residence located in Manhattan, New York.

On March 28, 2018, the singer went public on her Facebook page that she had systemic lupus, which caused her considerable pain and affected her ability to walk and stand. "The pain is so bad that I cry. I can hardly walk and now it's hard to stand",she said.

The singer died on Friday, June 10, at the age of 65, after a lifetime of struggling with lupus, a disease she had suffered from since youth.Although the cause of the disease in general is still unknown, but there is concrete evidence of the influence of genetics, epigenetics (changes in chromosomes that affect gene activity), environmental factors, viruses and infections.

For those of you who go back I thought you might want to know that I said goodbye to my wife, Julee Cruise, today. She left this realm on her own terms. No regrets. She is at peace. Having had such a varied music career she often said that the time she spent as a B filling in for Cindy while she was having a family was the happiest time of her performing life. She will be forever grateful to them. When she first stepped up the mic with Fred and Kate she said it was like joining the Beatles.She will love them always and never forget their travels together around the world. I played her Roam during her transition. Now she will roam forever. Rest In Peace, my love, and love to you all, wrote her husband to members of B-52 fan group.

As the husband said his last goodbye, his favorite song was Roam by The B-52's. The song Roam is a party piece by the group, with whom Cruise toured during the 1990s as a replacement for lead singer Cindy Wilson.

The fact that Grinnan decided to break the news to the band's fans first speaks volumes about his love for the group. His release was made on the fan group "the B-52's universe the world's greatest party band".

TV Shows

1. Twin Peaks (1990).Available on Paramount +

2. The Red Shoes (1983).

3. The Marvelous Land of Oz (1981).

4.Industrial Symphony No. 1: The Dream of the Brokenhearted (1990).

5.David Lynch: Don't Look at Me (1989)

6. The Red Shoes (1983).

7.Twin Peaks: Fire Walk with Me (1992).Available on HBO MAX.

8. Blue Velvet (1986). Available on Hulu, Kanopy, Tubi, Hoopla, The Criterion Channel and Paramount +.

9. Alice in Wonderland (1982).

10. Puss in Boots (1982).

Music

1.Floating into the Night (1989).Available on Spotify, Deezer and YouTube Music.

2.Cosmic Thing by The B-52's (1989). Available on Spotify, Deezer and YouTube Music.

3.Dance This Mess Around by The B-52's(1990). Available on Deezer.

4.The Voice of Love (1993). Available on Spotify and YouTube Music.

5.The Art of Being a Girl (2002). Available onSpotify and YouTube Music.

6.Julee Cruise/Nutcracker EP: An American Nightmare Maxi (2003).Available on Deezerand YouTube Music.

7.My Secret Life (2011).Available on Spotify, Deezer and YouTube Music.

Visit link:
Julee Cruise's Career: How and where to watch Twin Peaks and all her TV appearances - Bolavip US

Posted in Epigenetics | Comments Off on Julee Cruise’s Career: How and where to watch Twin Peaks and all her TV appearances – Bolavip US

Hitting the Pro Race Track: Onovi Health Adds Marko Radiic, Professional Race Car Driver & Entrepreneur, as a Brand Ambassador – PR Newswire

Posted: June 13, 2022 at 2:12 am

The high performance telehealth company Onovi believes the collaboration will help race car drivers & entrepreneurs improve performance on and off the track.

BIRMINGHAM, Ala., June 9, 2022 /PRNewswire/ -- Onovi, the leader in performance-driven men's healthcare, today announced a partnership with Marko Radiic of SRQ Motorsports Group. Radiic, an Onovi N1 client, represents Onovi in the SRO GTA America series powered by Amazon Web Services, Inc. Onovi Health is powered by the Gapin Institute for High Performance Medicine.

Just as race teams strategize and look for every tweak to improve the car's performance, Marko Radiic does the same with his personal health and performance. Radiic works with his medical and performance teams at Onovi to make precise adjustments off-track so he can perform better on-track.

"We are proud to partner with Marko Radiic and SRQ Motorsports on the upcoming GT America series," said Onovi CEO Clete Walker. "Marko has embraced the N1 Performance Health Program from Onovi Health and has been a fantastic example of how the program can improve endurance and stamina."

The physical toll of racing is far greater than many realize, and the drivers are required to function at optimal levels. The stressors faced by race car drivers include exposure to high G-force levels, heat stress, and intense muscular effort in addition to mental stress, dehydration, and more. With precision-based prep and recovery, a race car driver will have a competitive advantage to find their way into the winner's circle.

Tracy Gapin, MD, Chief Medical Officer for Onovi and creator of the N1 Performance Health Program said, "N1 is a personalized health program designed to optimize your mind and body for high performance. The program utilizes advanced breakthroughs in science and high performance medicine. N1 combines cutting-edge genetic & epigenetic science with the latest research in physiology, hormones, precision medicine and wearable technology. Whereas our current broken healthcare system only addresses disease, Onovi and the N1 program focus on health optimization."

The N1 Performance Health Program starts with baseline diagnostics and advanced lab testing to determine a precise health strategy. The program includes a medical doctor, functional health coach, nutritionist, fitness trainer, epigenetics specialist, and concierge team to interpret and leverage health data. Onovi also offers subscription services for hormone optimization, testosterone therapy, peptide therapy and at-home lab testing.

"The N1 Program dramatically improved my racing performance. The cutting-edge strategies and wearable tech helped me upgrade my health and training regimen, including my race-day approach. It also improved my personal and professional life, which is why I wanted to get involved with the brand. I'm excited to bring this level of precision to the professional racing circuit," said Radiic.

Radiic, the brand ambassador, is a great example of a high performer. The N1 program gives the 50-year-old race car driver and Guinness World Record holder, the extra edge in his health, training regimen and race day approaches. The data-driven program relies on wearable technology as one component of the systems-based precision approach.

Onovi http://www.onovihealth.com

About Onovi Health

Onovi Health, a high performance health company, provides a personalized, holistic and data-driven approach to provide a complete men's telehealth solution. Led by Urologists and men's health experts, Onovi combines cutting-edge genetic & epigenetic science with physiology, biochemistry, brain/peak performance, hormones and lifestyle for personalized solutions to reach peak performance. Onovi offers personalized men's health programs, telehealth services and at-home lab testing.

Related Links

Gapin Institute http://www.gapininstitute.com

Marko Radiic https://bit.ly/3auJyFY

Media Contact

Leann Spofford(941) 524-4592[emailprotected]

SOURCE Onovi Health

Visit link:
Hitting the Pro Race Track: Onovi Health Adds Marko Radiic, Professional Race Car Driver & Entrepreneur, as a Brand Ambassador - PR Newswire

Posted in Epigenetics | Comments Off on Hitting the Pro Race Track: Onovi Health Adds Marko Radiic, Professional Race Car Driver & Entrepreneur, as a Brand Ambassador – PR Newswire

Human genetics shape the gut microbiome – PMC

Posted: June 13, 2022 at 2:11 am

Summary

Host genetics and the gut microbiome can both influence metabolic phenotypes. However, whether host genetic variation shapes the gut microbiome and interacts with it to affect host phenotype is unclear. Here, we compared microbiotas across > 1,000 fecal samples obtained from the TwinsUK population, including 416 twin-pairs. We identified many microbial taxa whose abundances were influenced by host genetics. The most heritable taxon, the family Christensenellaceae, formed a cooccurrence network with other heritable Bacteria and with methanogenic Archaea. Furthermore, Christensenellaceae and its partners were enriched in individuals with low body mass index (BMI). An obese-associated microbiome was amended with Christensenella minuta, a cultured member of the Christensenellaceae, and transplanted to germfree mice. C. minuta amendment reduced weight gain and altered the microbiome of recipient mice. Our findings indicate that host genetics influence the composition of the human gut microbiome and can do so in ways that impact host metabolism.

The human gut microbiome has been linked to metabolic disease and obesity (Karlsson et al., 2013; Le Chatelier et al., 2013; Ley et al., 2005; Qin et al., 2012; Turnbaugh et al., 2009). Variation in host genetics can also underlie susceptibility to metabolic disease (Frayling et al., 2007; Frazer et al., 2009; Herbert et al., 2006; Yang et al., 2012). Despite these shared effects, the relationship between host genetic variation and the diversity of gut microbiomes is largely unknown.

The gut microbiome is environmentally acquired from birth (Costello et al., 2012; Walter and Ley, 2011), therefore it may function as an environmental factor that interacts with host genetics to shape phenotype, as well as a genetically determined attribute that is shaped by, and interacts with, the host (Bevins and Salzman, 2011; Spor et al., 2011; Tims et al., 2011). Because the microbiome can be modified for therapeutic applications (Borody and Khoruts, 2012; Hamilton et al., 2013; Khoruts et al., 2010; van Nood et al., 2013), it constitutes an attractive target for manipulation. Once the interactions between host genetics and the microbiome are understood, its manipulation could be optimized for a given host genome to reduce disease risk.

Although gut microbiomes can differ markedly in diversity across adults (Consortium, 2012; Qin et al., 2010), family members are often observed to have more similar microbiotas than unrelated individuals (Lee et al., 2011; Tims et al., 2013; Turnbaugh et al., 2009; Yatsunenko et al., 2012). Familial similarities are usually attributed to shared environmental influences, such as dietary preference, a powerful shaper of microbiome composition (Cotillard et al., 2013; David et al., 2013; Wu et al., 2011). Yet related individuals share a larger degree of genetic identity, raising the possibility that shared genetic composition underlies familial microbiome similarities.

Support for a host genetic effect on the microbiome comes mostly from studies taking a targeted approach. For instance, the concordance rate for carriage of the methanogen Methanobrevibacter smithii is higher for monozygotic (MZ) than dizygotic (DZ) twin pairs (Hansen et al., 2011), and studies comparing microbiotas between human subjects differing at specific genetic loci have shown gene-microbiota interactions (Frank et al., 2011; Khachatryan et al., 2008; Rausch et al., 2011; Rehman et al., 2011; Wacklin et al., 2011). A more general approach to this question has linked genetic loci with abundances of gut bacteria in mice (Benson et al., 2010; McKnite et al., 2012), but in humans, a general approach (e.g., using twins) has failed to reveal significant genotype effects on microbiome diversity (Turnbaugh et al., 2009; Yatsunenko et al., 2012). Thus, heritable components of the human gut microbiome remain to be identified using an unbiased approach.

Here, we assessed the heritability of the gut microbiome with a well-powered twin study. Comparisons between MZ and DZ twin pairs allowed us to assess the impact of genotype and early shared environment on their gut microbiota. Our study addressed the following questions: Which specific taxa within the gut microbiome are heritable, and to what extent? Which predicted metagenomic functions are heritable? How do heritable microbes relate to host BMI? Finally, we use fecal transplants into germfree mice to assess the phenotype effects of the most heritable taxon.

We obtained 1,081 fecal samples from 977 individuals: 171 MZ and 245 DZ twin pairs, 2 from twin pairs with unknown zygosity, and 143 samples from just one twin within a twinship (i.e., unrelated). In addition, we collected longitudinal samples from 98 of these individuals (see Supplemental Information). Most subjects were female, ranging in age from 23 to 86 years (average age: 60.6 0.3 years). The average BMI of the subjects was 26.25 ( 0.16) with the following distribution: 433 subjects had a low to normal BMI (<25), 322 had an overweight BMI (25-30), 183 were obese (>30) and 39 individuals in which the current BMI status was unknown. We generated 78,938,079 quality-filtered sequences that mapped to the Bacteria and Archaea in the Greengenes database (average sequences per sample: 73,023 889).

We sorted sequences into 9,646 operational taxonomic units (OTUs, 97% ID). Of these OTUs, 768 were present in at least 50% of the samples. Taxonomic classification revealed a fairly typical Western diversity profile: the dominant bacterial phyla were Firmicutes (53.9% of total sequences), Bacteroidetes (35.3%), Proteobacteria (4.5%), with Verrucomicrobia, Actinobacteria, and Tenericutes each comprising 2% of the sequences, and a tail of rare bacterial phyla that together accounted for the remaining 1% of the sequences.

The most widely shared methanogen was M. smithii (64% of people, using nonrarefied data), followed by vadinCA11, a member of the Thermoplasmata with no cultured representatives (~6%), Methanospheara stadtmanae (~4%), and Methanomassiliicoccus (~4%, a member of the Thermoplasmata). Forty-six of the 61 samples in which we detected vadinCA11 also contained M. smithii, indicating that the two most dominant archaeal taxa are not mutually exclusive. Faith's PD was positively correlated with the relative abundance of the family Methanobacteriaceae (rho = 0.42 rarefied, 0.37 for transformed counts, P < 1 x 1011), which corroborates previous reports of higher richness associating with methanogens.

We observed that microbiotas were more similar overall within individuals (resampled) than between unrelated individuals (P < 0.001 for weighted and unweighted UniFrac and Bray-Curtis using a Student's t-test with 1,000 Monte Carlo simulations; Table S1A), and were also more similar within twin pairs compared to unrelated individuals (P < 0.009 for weighted and unweighted UniFrac and Bray-Curtis; , S1 and Table S1). MZ twin pairs had more similar microbiotas than DZ twins for the unweighted UniFrac metric (P = 0.032), but not the weighted UniFrac and Bray-Curtis metrics (, S1). As greater similarities for MZ versus DZ twin pairs are seen in unweighted UniFrac but not abundance-based metrics, MZ similarities are driven by shared community membership rather than structure.

A, C-F: Box plots of beta-diversity distances between microbial communities obtained when comparing individuals within twinships for monozygotic (MZ) twin pairs and dizygotic (DZ) twin pairs, and between unrelated individuals (UN). A: the whole microbiome; C: the bacterial family Ruminococcaceae; D-E: the bacterial family Lachnospiraceae; F: the family Bacteroidaceae. The specific distance metric used in each analysis is indicated on the axes. *P<0.05, **P<0.01, ***P<0.001 for Student's t-tests with 1,000 Monte Carlo simulations. B: The average relative abundances in the whole dataset for the top six most prevalent bacterial families (unrarefied data, see Methods). Relates to Figure S1 and Table S1.

We next constrained the distance metric analyses to the three most dominant bacterial families: the Lachnospiraceae and Ruminococcaceae (Firmicutes) and Bacteroidaceae (). We observed greater similarities for MZ compared to DZ twins using the unweighted UniFrac metric within the Ruminococcaceae family (). Within the Lachnospiraceae family, significantly greater similarity for MZ compared to DZ twins emerged using the weighted UniFrac and Bray-Curtis metrics (). In contrast, when restricted to the Bacteroidaceae family, we found that MZ and DZ twins had similar pair-wise diversity using all three metrics (, S1B and S1E).

We next asked if the abundances of specific taxa were generally more highly correlated within MZ twin pairs compared to DZ twin pairs. For each twin pair we generated intraclass correlation coefficients (ICCs) for the relative abundances of OTUs. Mean ICCs were significantly greater for MZ compared to DZ twin pairs (Wilcoxon signed rank test on ICCs at the OTU level, P = 6 x 1004; ). Since many OTUs are closely phylogenetically related, their abundances may not be independent, which may inflate levels of significance. To account for this effect, we maintained the structure of the phylogenetic tree but permuted the MZ and DZ labels in 10,000 tests to generate randomized ICCs. As an independent validation, we also applied these analyses to two previously published datasets generated originating in a population of twins from Missouri, USA: Turnbaugh (Turnbaugh et al., 2009), which described 54 twin pairs ranging from 21-32 years of age, and Yatsunenko (Yatsunenko et al., 2012), which included 63 twin pairs with an age range of 13-30 years of age. Mean ICCs of OTU abundances were significantly greater for MZ compared to DZ twin pairs in both of these datasets (significance by permutation: P < 0.001 and 0.047 respectively; Figure S2), corroborating our observations.

At left is a phylogeny of taxa in the TwinsUK study (Greengenes tree pruned to include only OTUs shared by 50% of the TwinsUK participants) and at right are corresponding twin-pair intra class correlation coefficients (ICCs). ICCs were calculated for each OTU and the difference in correlation coefficients for MZ twin pairs versus DZ twin pairs. Bars pointing to the right indicate that the difference is positive (i.e., MZ ICCs > DZ ICCs) and bars pointing to the left indicate negative differences (DZ ICCs > MZ ICCs). The scale bar associated with the phylogeny shows substitutions/site. Relates to Figure S2.

We estimated heritability using the twin-based ACE model, which partitions the total variance into three component sources: genetic effects (A), common environment (C), and unique environment (E) (Eaves et al., 1978). The largest proportion of variance in abundances of OTUs could be attributed to the twins unique environments (i.e., E > A; Table S2). However, for the majority of OTUs (63%), the proportion of variance attributed to genetic effects was greater than the proportion of variance attributed to common environment (A > C; Table S2).

From the ACE model we calculated 95% confidence intervals for the heritability estimates, and determined the significance of the heritability values using a permutation method to generate nominal P values (Table S2). We found a high correlation between the tail probability for inclusion of zero in the confidence interval of heritability and the P values obtained from the permutation tests (rho = 0.872, P < 1015), indicating substantial consistency across these tests. Although heritability studies traditionally report confidence intervals and nominal P values only, we also generated FDR-corrected P values (Table S2).

We also applied the ACE model to the abundances of sequences mapping to each node in the phylogeny. Across the three studies, the nodes of the phylogeny with the strongest heritabilities lie within the Ruminococcaceae and Lachnospiraceae families, and the Bacteroidetes are mostly environmentally determined ( and S3). Subsets of the Archaea are also heritable in the TwinsUK and the Yatsunenko studies (the Turnbaugh study did not include data for Archaea).

A: OTU Heritability (A from ACE model) estimates mapped onto a microbial phylogeny and displayed using a rainbow gradient from blue (A = 0) to red (A 0.4). This phylogenetic tree was obtained from the Greengenes database and pruned to include only nodes for which at least 50% of the TwinsUK participants were represented. B: The significance for the heritability values shown in A was determined using a permutation test (n=1,000) and are shown on the same phylogeny as in panel A. P values range from 0 (red) to >0.1 (blue). Relates to Figure S3 and Table S2.

We characterized the longitudinal stability of each OTU by calculating the ICCs of the OTU abundance across repeat samples, which consisted of two samples collected from the same individual at different times. By permuting these repeat sample ICCs, we found that heritable OTUs (A > 0.2) were more stable (ICC > 0.6) than expected by chance (Figure S3E; P < 0.001, P value was determined as the fraction of permutations that had greater than or equal to the observed number of OTUs that are both heritable and stable).

We used PICRUSt (Langille et al., 2013) to produce predicted metagenomes from the 16S rRNA gene sequence data and applied the ACE model to estimate the heritability of predicted abundances of conserved orthologous groups (COGs). This analysis revealed 6 functions with heritabilities A > 0.2 and nominal P values < 0.05 (P values are generated by permutation testing; Supplementary Methods; Table S2). Correcting for multiple comparisons, one category, secondary metabolites biosynthesis, transport and catabolism (Q), passed a stringent FDR (A = 0.32, 95% CI = 0.16-0.44). We also tested alpha diversity for heritability and found that it was not heritable.

The most heritable taxon overall was the family Christensenellaceae (A = 0.39, 95% confidence interval 0.21-0.49, P = 0.001, and Table S2; this taxon passes a stringent FDR) of the order Clostridiales. Christensenellaceae was also highly heritable in the Yatsunenko dataset (A = 0.62, 95% confidence interval 0.38-0.77; and Table S2). We repeated this analysis for the taxa abundances with the effect of BMI regressed out, and results were highly correlated (Pearson correlation = 0.95, P < 11015).

Scatter plots comparing the abundances of Christensenellaceae in the gut microbiota of MZ and DZ co-twins. Christensenellaceae abundances were transformed and adjusted to control for technical and other covariates (Residuals are plotted, see Supplemental Methods) and the data are separated by zygosity (MZ or DZ twins). A: TwinsUK dataset. B: Yatsunenko dataset.

We observe a module of co-occurring heritable families, and the hub (node connected to most other nodes) of this module is the family Christensenellaceae ( and S4A). The heritable module includes the families Methanobacteriaceae (Archaea) and Dehalobacteriaceae (Firmicutes) and the orders SHA-98 (Firmicutes), RF39 (Tenericutes) and ML615J-28 (Tenericutes). The Christensenellaceae-network is anti-correlated with the Bacteroidaceae and Bifidobacteriaceae families. We validated these results by applying this method to the family-level taxonomic abundances in the Yatsunenko dataset (as this one is most technically similar to the TwinsUK dataset), where we also found the same Christensenellaceae-centered module of heritable families anti-correlated to the Bacteroidaceae/Bifidobacteriaceae module (Figure S4B).

A and B show the same network built from SparCC correlation coefficients between sequence abundances collapsed at the family level. The nodes represent families and the edges represent the correlation coefficients between families. Edges are colored blue for a positive correlation and grey for a negative correlation, and the weight of the edge reflects the strength of the correlation. Nodes are positioned using an edge-weighted force directed layout. In panel A, the nodes are colored by the heritability of the family, and in panel B, the nodes are colored by the significance of the association families and a normal vs. obese BMI. Family names are either indicated on the panel, or nodes are given a letter code. Phylum Actinobacteria: (a) Actinomycetaceae, (b) Coriobacteriaceae; Phylum Bacteroidetes: (c) Barnesiellaceae, (d) Odoribacteraceae, (e) Paraprevotellaceae, (f) Porphyromonadaceae, (g) Prevotellaceae, (h) Rikenellaceae; Phylum Firmicutes: (i) Carnobacteriaceae, (j) Clostridiaceae, (k) Erysipelotrichaceae, (l) Eubacteriaceae, (m) Lachnospiraceae, (n) Lactobacillaceae, (o) Mogibacteriaceae, (p) Peptococcaceae, (q) Peptostreptococcaceae, (r) Ruminococcaceae, (s) Streptococcaceae, (t) Tissierellaceae, (u) Turicibacteraceae, (v) Unclassified Clostridiales, (w) Veillonellaceae; Phylum Proteobacteria: (x) Alcaligenaceae, (y) Enterobacteriaceae, (z) Oxalobacteraceae, (aa) Pasteurellaceae, (ab) Unclassified RF32; Phylum Verrucomicrobia: (ac) Verrucomicrobiaceae. Relates to Figure S4.

The family Christensenellaceae was significantly enriched in subjects with a lean BMI (< 25) compared to those with an obese BMI (> 30; Benjamini-Hochberg corrected P value < 0.05 from t-test on transformed counts; Table S2). Other members of the Christensenellaceae consortium were also enriched in lean-BMI subjects: the Dehalobacteriaceae, SHA-98, RF39, and the Methanobacteriaceae (). Overall, a majority (n=35) of the OTUs with highest heritability scores (A > 0.2, nominal P < 0.05) were enriched in the lean subjects. A subset of OTUs classified as Oscillospira were enriched in lean subjects, and M. smithii, though not significantly heritable, was positively associated with a lean BMI.

Because the names Christensenella and Christensenellaceae were only recently assigned to the bacterial phylogeny, we assessed the abundances of sequences assigned to these taxa in previously published studies. This analysis revealed that members of the Christensenellaceae were enriched in fecal samples of healthy versus pediatric and young adult IBD patients (P < 0.05) (Papa et al., 2012). Christensenellaceae were at greater abundance in lean-BMI compared to obese-BMI twins in the Turnbaugh dataset but the difference was not quite significant (time-point 2 samples, P = 0.07). In a case study of the development of an infant's gut microbiome (Koenig et al., 2011), Christensenellaceae was present at 8.6% in the mother's stool at the time of birth, and at 20% in the infant's meconium. We also noted that Christensenellaceae is enriched in omnivorous compared to herbivorous and carnivorous mammals (Muegge et al., 2011). However, we did not find a relationship between Christensenellaceae and diet information in human studies (Wu et al., 2011; Martinez et al., 2010; Koren et al., 2012).

Methanogens co-occurred with Christensenellaceae in this study and have been linked to low BMI in previous studies. Because of this previous association with a low-BMI, we wanted to ensure that methanogens were present in the Christensenellaceae consortium in an initial experiment exploring its effect on weight phenotypes. Therefore, we selected 21 donors for fecal transfer to germfree mice based on BMI status (low or high) and presence or absence of the methanogen-Christensenellaceae consortium. Donors fell into one of four categories: lean with detectable methanogens (L+), lean without methanogens (L-), obese with methanogens (O+), or obese without methanogens (O-). The abundance of Christensenellaceae positively correlated with the abundance of methanogens in donor stool (rho=0.72, P=0.0002), indicating that methanogen abundance was a good proxy for the methanogen-Christensenellaceae consortium.

A 16S rRNA analysis of the fecal microbiomes before and after transfer to germfree mice showed that although members of the Christensenellaceae were present throughout the experiment in recipient mice (), M. smithii was undetectable in the mouse fecal or cecal samples (the first sampling was at 20hrs post-inoculation). At 20 hrs post-inoculation, the microbiota had shifted dramatically in diversity from the inoculation, but by Day 5 had shifted back partially and remained fairly stable through Day 21 (, S5A, and S5B). Abundances of Christensenella were correlated with PC3 (abundances rarefied at 55,000 sequences per sample vs. unweighted UniFrac; Spearman rho = 0.59, P < 2.2 x 1016), and PC3 captured the differences between the 4 donor groups (). We observed a trend for Christensenella abundances as highest in the L+ group and lowest in the O- group (), which mirrored the weight differences between those groups: the percent change in body weights of the recipient mice was significantly lower in the L+ group compared to the O- group (Day 12, P < 0.05, t-test; ). Cecal levels of propionate and butyrate were significantly elevated in mice receiving methanogen-positive compared to methanogen-negative microbiomes controlling for the effect of donor BMI (two-way ANOVA, P < 0.05 for both SCFAs, Figures S5C-E). Stool energy content was significantly higher for the methanogen-positive microbiomes at Day 12, when the percent changes in weight were greatest (two-way ANOVA, P = 0.004, no effect of BMI or interaction; Figure S5F). In a replicated experiment, using 21 new donors, the same weight differences were observed (a significantly lower mean weight gain for the L+ compared to the O- mouse recipients at Day 10 post-inoculation; one-way t-test, P = 0.047; Figure S5G).

A: Median relative abundances for OTUs classified as the genus Christensenella in the four donor treatment groups over time in the recipient mouse microbiotas. B: Principal coordinates analysis of unweighted UniFrac distances for (i) the inoculum prior to transplantation, (ii) fecal samples at 4 time points, and (iii) cecal samples at Day 21 post-transplant; see panel legend for color key. The amount of variance described by the first two PCs is shown on the axes. C: Richness (Faith's PD) for the microbiomes of the transplant mice plotted against time (days post inoculation, with Day 0 = inoculation day). D: The mean values S.E.M. for PC3 derived for the same analysis as shown in panel B are plotted against time (Day 0 = inoculation day) for the four treatment groups. The amount of variance explained by PC3 is in parentheses. E: Percent weight change since inoculation for germfree mouse recipients of 21 donor stools that were obtained from lean or obese donors with or without detectable M. smithii, which was used as a marker for the Christensenellaceae consortium. Means for each treatment group are plotted S. E. M. F: Box plots for percent weight changes for the 4 groups at Day 12 post-transplant, when maximal weight differences were observed. Letters next to boxes indicate significant differences if letters are different (p < 0.05). For all panels, Dark blue = L+, lean donor with methanogens; Light blue = L-, lean donor lacking methanogens; Dark orange = O+, obese donor with methanogens; Light orange = O-, obese donor without methanogens. We repeated this experiment with a set of 21 new mice and unique human donors and recovered the same effect. Relates to Figure S5.

Based on the observation that Christensenella levels in the previous experiment were similar to the weight gain patterns, we performed experiments in which a donor stool lacking detectable Christensenella was amended with C. minuta and weight gain of recipient mice was monitored. One obese human donor was selected from the 21 donors from the first transplant experiment based on its lack of detectable OTUs assigned to the genus Christensenella. At Day 21 post-gavage, mice receiving the C. minuta treatment weighed significantly less than those that received unamended stool (nested ANOVA, P < 0.05, ). Adiposity was significantly lower for mice receiving the C. minuta treatment (nested ANOVA, P = 9.4 x 105, ). Energy content for stool collected at Day 21 was not different between treatments (data not shown).

A: Box plot of percent weight change for germfree mouse recipients of a single donor stool only (lacking detectable Christensenella in unrarefied 16S rRNA data) or the donor stool amended with live C. minuta. B: Box plots showing percent body fat for mice in each group at Day 21 N = 12 mice per treatment. C, D: Principal coordinates analysis of unweighted UniFrac distances for (i) the inoculum prior to transplantation, (ii) fecal samples at 5 time points post-transplant; see panel legend for color key. The amount of variance described by the first two PCs is shown on the axes. The same data projection is shown in panels C and D; sample symbols are colored by time point (C) and by treatment (D). E: Relationship between PCs from the PCoA analysis and levels of Oscillospira at Day 21 (rho = 0.71, P = P < 0.001). Symbols are colored by treatment. Relates to Figure S6.

Analysis of the microbial community by 16S rRNA gene sequencing showed an impact on the overall community diversity that persisted over time (). After an initial acclimation (20 h), the communities within recipient mice began to separate by treatment regardless of the effects of time and co-caging ( and S6). At 5 days post-inoculation, the relative abundance of C. minuta was similar to that observed in the previous transplant experiment and persisted throughout the duration of the study. We identified two genera that discriminated the two treatments at Day 21: Oscillospira and a genus within the Rikenellaceae were enriched in the C. minuta treatment (misclassification error rate of 0.06). Oscillospira abundances were significantly correlated with PC2 in the unweighted UniFrac analysis of the communities (rho = 0.71, P = 0.0009; ), which is the PC that separates the C. minuta-amended and unamended microbiotas.

Our results represent the first strong evidence that the abundances of specific members of the gut microbiota are influenced in part by the genetic makeup of the host. Earlier studies using fingerprinting approaches also reported host genetic effects (Stewart et al., 2005; Zoetendal et al., 2001), but without sequence data it is not possible to know if the taxa shown here to be heritable were also driving those patterns. The Turnbaugh et al. and Yatsunenko et al. studies, which are quite similar in experimental approach, reported a lack of host genetic effect on the gut microbiome, most likely because both studies were underpowered. Nevertheless, re-analysis of the data from both studies validated our observation that the abundances of taxa are more highly correlated within MZ than DZ twin pairs. Thus, host genetic interactions with specific taxa are likely widespread across human populations, with profound implications for human biology.

The most highly heritable taxon in our dataset was the family Christensenellaceae, which was also the hub of a co-occurrence network that includes other taxa with high heritability. A notable component of this network was the archaeal family Methanobacteriaceae. Similarly, Hansen et al. had previously identified members of the Christensenellaceae (reported as relatives of Catabacter) as co-occurring with M. smithii (Hansen et al., 2010). These co-occurrence patterns could derive from different scenarios: for instance, multiple taxa may be heritable and co-occur while each taxon is affected by host genetics independently, or alternatively one (or a few) taxa may be heritable and other taxa correlate with host genetics due to their co-occurrence with these key heritable taxa. Further experimental research will be required to elucidate if the co-occurring heritable taxa interact in syntrophic partnerships or simply respond similarly to host-influenced environmental cues in the gut.

Our results suggest that environmental factors mostly shape the Bacteroidetes community, since most were not heritable. These results are consistent with those of a recent study of Finnish MZ twins, in which levels of Bacteroides spp. were more similar between twins when their diets were similar (Simoes et al., 2013). Members of the Bacteroidetes have been shown to respond to diet interventions (Wu et al., 2011; David et al. 2013)

Importantly, the family Christensenellaceae is heritable in the Yatsunenko dataset and its network is also present. This validation did not involve a directed search using the taxa identified in this study but was made by applying the ACE model independently. In the TwinsUK as well as the Missouri twins datasets, the majority of OTUs with the highest heritability estimates fell within the Ruminococcaceae and Lachnospiraceae families. The Missouri and TwinsUK studies differed somewhat in the levels and structure of heritability, which may relate to study size (Kuczynski et al., 2010), participant age (Claesson et al., 2011), population (Yatsunenko et al., 2012), and/or diet (Wu et al., 2011), all of which have been shown to affect microbiome structure.

The high heritability of the Christensenellaceae raises questions about the nature of interactions between the host and members of this family, but to date there is little published work with which to infer their roles. Christensenella minuta is Gram-negative, non-spore forming, non-motile, and produces SCFAs (Morotomi et al., 2012). A review of publicly available data suggests it is present from birth and associates with a healthy state but not with diet. Thus, although diet is a heritable trait in the same population (Menni et al., 2013; Teucher et al., 2007), it does not appear to be driving the heritability of the Christensenellaceae. Obesity is also strongly heritable in the TwinsUK population, raising the question of whether the heritabilities we saw for gut microbes were driven by BMI. To test this, we reran the heritability calculations using residuals after regressing out the effect of BMI and found that results of the two analyses were highly correlated. This suggests that the effect of host genetics on Christensenellaceae abundance is independent of an effect of BMI.

Our transplantation experiments showed a moderating effect of methanogen-presence in the human donor on weight gain of recipient mice, although strikingly, M. smithii did not persist in mice. In contrast, Christensenellaceae levels in mice mirrored their weight gain. Transfer to germfree mice of microbiomes from obese and lean donors generally results in greater adiposity gains for obese compared to lean donors (Ridaura et al., 2013; Turnbaugh et al., 2008; Vijay-Kumar et al., 2010). These studies have not reported the methanogen or Christensenellaceae status of the donors, so whether these microbes affect the host phenotype is unknown. M. smithii has been associated with a lean phenotype in multiple studies (Million et al., 2013; Million et al., 2012; Schwiertz et al., 2010; Armougom et al., 2009; Le Chatelier, 2013), raising the possibility that methanogens are key components of the consortium for regulating host phenotype. The results of our methanogen-Christensenellaceae transfer revealed that although methanogens may be a marker for a low BMI in humans, they are not required to promote a lean phenotype in the germfree mouse experimental model. This result suggests that methanogens may be functionally replaced by another consortium member in the mouse, while the Christensenellaceae are not.

The results of the C. minuta spike-in experiments supported the hypothesis that members of the Christensenellaceae promote a lean host phenotype. Addition of C. minuta also remodeled the diversity of the community. Intriguingly, Oscillospira, which includes heritable OTUs in the TwinsUK dataset and is associated with a lean BMI, was enriched in the C. minuta-amended microbiomes. How C. minuta reshapes the community remains to be explored. The relatively low levels of C. minuta and its profound effects on the community and the host may indicate that it is a keystone taxon. Together these findings indicate that the Christensenellaceae are highly heritable bacteria that can directly contribute to the host phenotype with which they associate.

Fecal samples were obtained from adult twin pair participants of the TwinsUK registry (Moayyeri, 2013). Most participants were women (only 20 men were included). Twins collected fecal samples at home, and the samples were refrigerated for up to 2 days prior to their annual clinical visit at King's College London, at which pointed they were stored at 80C until processing.

We amplified 16S rRNA genes (V4) from bulk DNA by PCR prior to sequencing on the Illumina MiSeq 2x250bp platform at Cornell Biotechnology Resource Center Genomics Facility. We performed quality filtering and analysis of the 16S rRNA gene sequence data with QIIME 1.7.0 (Caporaso et al., 2010).

PICRUSt v1.0.0 was used to predict abundances of COGs from the OTU abundances rarefied at 10,000 sequences per sample.

Heritability estimates were calculated on the OTU abundances, taxon bins, nodes throughout the bacterial phylogenetic tree, -diversity, and PICRUSt-predicted COGs using the structural equation modeling software OpenMx (Boker et al., 2011).

Stool samples from the Twins UK cohort were selected as described in the main text and inoculated into 6-week old germ-free Swiss Webster mice via oral gavage, with one recipient mouse per fecal donor. Mice were single-housed. For the Christensenella minuta addition, three experiments were conducted: In the first experiment, one treatment group received only donor stool inoculum, whereas the other received donor stool amended with 1 108C. minuta cells;for the second experiment, a heat-killed C. minuta control was added; in the third experiment, the heat-killed control was compared to live C. minuta only (no vehicle-only control). Mice were housed 4 per cage, with 3 cages per treatment. In all experiments, mice were provided with autoclaved food and water ad libitum and maintained on a 12-hr light/dark cycle. Body weight and chow consumption were monitored and fecal pellets were collected weekly. At sacrifice, adiposity was analyzed using DEXA. Body, mesenteric adipose tissue, and gonadal fat pad tissue weights were collected at this time. Gross energy content of mouse stool samples was measured by bomb calorimetry using an IKA C2000 calorimeter (Dairy One, Ithaca, NY). Wet cecal contents were weighed and resuspended in 2% (v/v) formic acid by vortexing and measured using a gas chromatograph (HP series 6890) with flame ionization detection.

Values are expressed as the mean SEM unless otherwise indicated. Full methods are described in the Supplemental Information

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Author Contributions: R.E.L. and A.G.C. supervised the study, and J.T.B. and T.D.S. helped design study and provided comments and discussion. J.T.B. and T.D.S. oversaw collection of samples; J.K.G., R.E.L., O.K., J.L.S., A.C.P, J.L.W. oversaw microbial data generation; J.K.G. performed the analysis with contributions from R.E.L, R.B., A.G.C., J.L.W., O.K., A.C.P, M.B., W.V.T. and R.K; J.K.G. and J.L.W. performed microbiota transfer experiments; J.K.G., J. L.W and R.E.L. prepared the manuscript, with comments from A.G.C, T.D.S, J.T.B, R.B., and R.K.

Author Information: The 16S rRNA gene sequences have been deposited in the European Nucleotide Archive (ENA), European Bioinformatics Institute, with accession numbers ERP006339 and ERP006342.

SUPPLEMENTAL INFORMATION

Supplemental Information includes Extended Experimental Procedures and data and can be found with this article online.

More:
Human genetics shape the gut microbiome - PMC

Posted in Human Genetics | Comments Off on Human genetics shape the gut microbiome – PMC

New Comprehensive Map Ties Every Human Gene to Its Function – SciTechDaily

Posted: June 13, 2022 at 2:11 am

Data for a new gene-function map are available for other scientists to use. Its a big resource in the way the human genome is a big resource, in that you can go in and do discovery-based research, says Professor Jonathan Weissman.

Scientists used their single-cell sequencing tool Perturb-seq on every expressed gene in the human genome, linking each to its job in the cell.

Genetics research has advanced rapidly over the last few decades. For example, just a few months ago scientists announced the first complete, gap-free human genome sequencing. Now researchers have advanced again, creating the first comprehensive functional map of genes that are expressed in human cells.

The Human Genome Project was an ambitious initiative to sequence every piece of human DNA. The project drew together collaborators from research institutions around the world, including MITs Whitehead Institute for Biomedical Research, and was finally completed in 2003. Now, over two decades later, MIT Professor Jonathan Weissman and colleagues have gone beyond the sequence to present the first comprehensive functional map of genes that are expressed in human cells. The data from this project, published online on June 9, 2022, in the journal Cell, ties each gene to its job in the cell, and is the culmination of years of collaboration on the single-cell sequencing method Perturb-seq.

The data are available for other scientists to use. Its a big resource in the way the human genome is a big resource, in that you can go in and do discovery-based research, says Weissman, who is also a member of the Whitehead Institute and an investigator with the Howard Hughes Medical Institute. Rather than defining ahead of time what biology youre going to be looking at, you have this map of the genotype-phenotype relationships and you can go in and screen the database without having to do any experiments.

CRISPR, which stands for clustered regularly-interspaced short palindromic repeats, a genome editing tool invented in 2009 made it easier than ever to edit DNA. It is easier, faster, less expensive, and more accurate than previous genetic editing methods.

The screen allowed the researchers to delve into diverse biological questions. They used it to explore the cellular effects of genes with unknown functions, to investigate the response of mitochondria to stress, and to screen for genes that cause chromosomes to be lost or gained, a phenotype that has proved difficult to study in the past. I think this dataset is going to enable all sorts of analyses that we havent even thought up yet by people who come from other parts of biology, and suddenly they just have this available to draw on, says former Weissman Lab postdoc Tom Norman, a co-senior author of the paper.

Pioneering Perturb-seq

The project takes advantage of the Perturb-seq approach that makes it possible to follow the impact of turning on or off genes with unprecedented depth. This method was first published in 2016 by a group of researchers including Weissman and fellow MIT professor Aviv Regev, but could only be used on small sets of genes and at great expense.

The massive Perturb-seq map was made possible by foundational work from Joseph Replogle, an MD-PhD student in Weissmans lab and co-first author of the present paper. Replogle, in collaboration with Norman, who now leads a lab at Memorial Sloan Kettering Cancer Center; Britt Adamson, an assistant professor in the Department of Molecular Biology at Princeton University; and a group at 10x Genomics, set out to create a new version of Perturb-seq that could be scaled up. The researchers published a proof-of-concept paper in Nature Biotechnology in 2020.

The Perturb-seq method uses CRISPR-Cas9 genome editing to introduce genetic changes into cells, and then uses single-cell RNA sequencing to capture information about the RNAs that are expressed resulting from a given genetic change. Because RNAs control all aspects of how cells behave, this method can help decode the many cellular effects of genetic changes.

Since their initial proof-of-concept paper, Weissman, Regev, and others have used this sequencing method on smaller scales. For example, the researchers used Perturb-seq in 2021 to explore how human and viral genes interact over the course of an infection with HCMV, a common herpesvirus.

In the new study, Replogle and collaborators including Reuben Saunders, a graduate student in Weissmans lab and co-first author of the paper, scaled up the method to the entire genome. Using human blood cancer cell lines as well noncancerous cells derived from the retina, he performed Perturb-seq across more than 2.5 million cells, and used the data to build a comprehensive map tying genotypes to phenotypes.

Delving into the data

Upon completing the screen, the researchers decided to put their new dataset to use and examine a few biological questions. The advantage of Perturb-seq is it lets you get a big dataset in an unbiased way, says Tom Norman. No one knows entirely what the limits are of what you can get out of that kind of dataset. Now, the question is, what do you actually do with it?

The first, most obvious application was to look into genes with unknown functions. Because the screen also read out phenotypes of many known genes, the researchers could use the data to compare unknown genes to known ones and look for similar transcriptional outcomes, which could suggest the gene products worked together as part of a larger complex.

The mutation of one gene called C7orf26 in particular stood out. Researchers noticed that genes whose removal led to a similar phenotype were part of a protein complex called Integrator that played a role in creating small nuclear RNAs. The Integrator complex is made up of many smaller subunits previous studies had suggested 14 individual proteins and the researchers were able to confirm that C7orf26 made up a 15th component of the complex.

They also discovered that the 15 subunits worked together in smaller modules to perform specific functions within the Integrator complex. Absent this thousand-foot-high view of the situation, it was not so clear that these different modules were so functionally distinct, says Saunders.

Another perk of Perturb-seq is that because the assay focuses on single cells, the researchers could use the data to look at more complex phenotypes that become muddied when they are studied together with data from other cells. We often take all the cells where gene X is knocked down and average them together to look at how they changed, Weissman says. But sometimes when you knock down a gene, different cells that are losing that same gene behave differently, and that behavior may be missed by the average.

The researchers found that a subset of genes whose removal led to different outcomes from cell to cell were responsible for chromosome segregation. Their removal was causing cells to lose a chromosome or pick up an extra one, a condition known as aneuploidy. You couldnt predict what the transcriptional response to losing this gene was because it depended on the secondary effect of what chromosome you gained or lost, Weissman says. We realized we could then turn this around and create this composite phenotype looking for signatures of chromosomes being gained and lost. In this way, weve done the first genome-wide screen for factors that are required for the correct segregation of DNA.

I think the aneuploidy study is the most interesting application of this data so far, Norman says. It captures a phenotype that you can only get using a single-cell readout. You cant go after it any other way.

The researchers also used their dataset to study how mitochondria responded to stress. Mitochondria, which evolved from free-living bacteria, carry 13 genes in their genomes. Within the nuclear DNA, around 1,000 genes are somehow related to mitochondrial function. People have been interested for a long time in how nuclear and mitochondrial DNA are coordinated and regulated in different cellular conditions, especially when a cell is stressed, Replogle says.

The researchers found that when they perturbed different mitochondria-related genes, the nuclear genome responded similarly to many different genetic changes. However, the mitochondrial genome responses were much more variable.

Theres still an open question of why mitochondria still have their own DNA, said Replogle. A big-picture takeaway from our work is that one benefit of having a separate mitochondrial genome might be having localized or very specific genetic regulation in response to different stressors.

If you have one mitochondria thats broken, and another one that is broken in a different way, those mitochondria could be responding differentially, Weissman says.

In the future, the researchers hope to use Perturb-seq on different types of cells besides the cancer cell line they started in. They also hope to continue to explore their map of gene functions, and hope others will do the same. This really is the culmination of many years of work by the authors and other collaborators, and Im really pleased to see it continue to succeed and expand, says Norman.

Reference: Mapping information-rich genotype-phenotype landscapes with genome-scale Perturb-seq by Joseph M. Replogle, Reuben A. Saunders, Angela N. Pogson, Jeffrey A. Hussmann, Alexander Lenail, Alina Guna, Lauren Mascibroda, Eric J. Wagner, Karen Adelman, Gila Lithwick-Yanai, Nika Iremadze, Florian Oberstrass, Doron Lipson, Jessica L. Bonnar, Marco Jost, Thomas M. Norman and Jonathan S. Weissman, 9 June 2022, Cell.DOI: 10.1016/j.cell.2022.05.013

View post:
New Comprehensive Map Ties Every Human Gene to Its Function - SciTechDaily

Posted in Human Genetics | Comments Off on New Comprehensive Map Ties Every Human Gene to Its Function – SciTechDaily

Page 398«..1020..397398399400..410420..»